Back HCV Treatment

DDW 2016: Sofosbuvir/ Velpatasvir Produces High Hepatitis C Cure Rates in ASTRAL Trials

A coformulation of Gilead Science's sofosbuvir and its investigational hepatitis C virus (HCV) NS5A inhibitor velpatasvir taken for 12 weeks produced sustained virological response in 95% to 99% of participants across HCV genotypes and led to improvements in patient-reported outcomes, according to a pair of studies presented at the 2016 Digestive Disease Week meeting this week in San Diego.


Read more: